Here, we review the research that has demonstrated Dyrk1B to be a valuable therapeutic target in cancer, and we refer to efforts and recent advances in the field of medicinal chemistry aimed at generating potent and highly specific Dyrk1B inhibitors exhibiting eliminated off-target effects against other kinases and especially its closely related member Dyrk1A. The gene discussed is DYRK1A; the disease is cancer.